Halozyme Therapeutics, Inc. (HALO): Price and Financial Metrics

Halozyme Therapeutics, Inc. (HALO): $40.37

0.49 (-1.20%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

B

Add HALO to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#15 of 360

in industry

HALO Price/Volume Stats

Current price $40.37 52-week high $45.00
Prev. close $40.86 52-week low $29.85
Day low $40.32 Volume 1,046,300
Day high $40.96 Avg. volume 1,438,836
50-day MA $37.07 Dividend yield N/A
200-day MA $38.18 Market Cap 5.13B

HALO Stock Price Chart Interactive Chart >

HALO POWR Grades

  • HALO scores best on the Value dimension, with a Value rank ahead of 89.68% of US stocks.
  • The strongest trend for HALO is in Quality, which has been heading up over the past 26 weeks.
  • HALO ranks lowest in Momentum; there it ranks in the 10th percentile.

HALO Stock Summary

  • For HALO, its debt to operating expenses ratio is greater than that reported by 82.97% of US equities we're observing.
  • HALO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 92.45% of US stocks.
  • As for revenue growth, note that HALO's revenue has grown 34.46% over the past 12 months; that beats the revenue growth of 86.74% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to HALOZYME THERAPEUTICS INC, a group of peers worth examining would be LYFT, ACIW, ZUO, OPGN, and NTAP.
  • Visit HALO's SEC page to see the company's official filings. To visit the company's web site, go to www.halozyme.com.

HALO Valuation Summary

  • In comparison to the median Healthcare stock, HALO's price/sales ratio is 186.36% higher, now standing at 6.3.
  • Over the past 241 months, HALO's price/sales ratio has gone down 133.4.

Below are key valuation metrics over time for HALO.

Stock Date P/S P/B P/E EV/EBIT
HALO 2023-12-29 6.3 19.6 19.2 18.2
HALO 2023-12-28 6.3 19.7 19.3 18.2
HALO 2023-12-27 6.2 19.6 19.2 18.1
HALO 2023-12-26 6.3 19.8 19.4 18.3
HALO 2023-12-22 6.3 19.7 19.3 18.2
HALO 2023-12-21 6.2 19.6 19.2 18.1

HALO Growth Metrics

    The 5 year price growth rate now stands at 79.34%.
  • The 5 year net income to common stockholders growth rate now stands at 30.98%.
  • The 2 year cash and equivalents growth rate now stands at 12.36%.
Over the past 52 months, HALO's revenue has gone up $378,922,000.

The table below shows HALO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 660.116 240.11 202.129
2022-09-30 580.623 240.173 211.197
2022-06-30 487.477 292.277 366.15
2022-03-31 471.567 288.941 434.923
2021-12-31 443.31 299.44 402.71
2021-09-30 463.01 267.844 409.104

HALO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HALO has a Quality Grade of C, ranking ahead of 73.97% of graded US stocks.
  • HALO's asset turnover comes in at 0.493 -- ranking 84th of 682 Pharmaceutical Products stocks.
  • ARAV, XOMA, and MGNX are the stocks whose asset turnover ratios are most correlated with HALO.

The table below shows HALO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.493 0.814 0.250
2021-06-30 0.533 0.823 0.255
2021-03-31 0.510 0.832 0.224
2020-12-31 0.504 0.838 0.220
2020-09-30 0.378 0.831 0.053
2020-06-30 0.369 0.720 -0.037

HALO Price Target

For more insight on analysts targets of HALO, see our HALO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $52.82 Average Broker Recommendation 1.62 (Moderate Buy)

Halozyme Therapeutics, Inc. (HALO) Company Bio


Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. The company was founded in 1998 and is based in San Diego, California.


HALO Latest News Stream


Event/Time News Detail
Loading, please wait...

HALO Latest Social Stream


Loading social stream, please wait...

View Full HALO Social Stream

Latest HALO News From Around the Web

Below are the latest news stories about HALOZYME THERAPEUTICS INC that investors may wish to consider to help them evaluate HALO as an investment opportunity.

Insider Sell Alert: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of ...

Halozyme Therapeutics Inc (NASDAQ:HALO), a biopharmaceutical company known for its novel enzyme technology that targets the extracellular matrix, has recently witnessed a significant insider sell transaction.

Yahoo | December 15, 2023

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)

Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.

Yahoo | December 14, 2023

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Yahoo | December 8, 2023

Why Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 6, 2023

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Yahoo | December 5, 2023

Read More 'HALO' Stories Here

HALO Price Returns

1-mo 11.83%
3-mo 10.97%
6-mo 1.15%
1-year 15.94%
3-year -8.52%
5-year 144.67%
YTD 9.23%
2023 -35.04%
2022 41.51%
2021 -5.85%
2020 140.89%
2019 21.19%

Continue Researching HALO

Want to see what other sources are saying about Halozyme Therapeutics Inc's financials and stock price? Try the links below:

Halozyme Therapeutics Inc (HALO) Stock Price | Nasdaq
Halozyme Therapeutics Inc (HALO) Stock Quote, History and News - Yahoo Finance
Halozyme Therapeutics Inc (HALO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!